Baculoviral IAP repeat-containing protein 5 peptide–Major Histocompatibility Complex class I complex (BIRC5 peptide–MHC class I complex)

The Baculoviral IAP repeat-containing protein 5 (BIRC5) peptide–Major Histocompatibility Complex (MHC) class I complex is a tumor-associated antigen (TAA) presented on the surface of malignant cells (Source: PubMed, PMID: 30233153). BIRC5, also known as Survivin, is a member of the inhibitor of apoptosis (IAP) protein family that is highly expressed in most human cancers but nearly absent in terminally differentiated normal tissues (Source: UniProt, O15392). This differential expression makes the Survivin-derived peptides, when presented by MHC class I molecules such as HLA-A*02:01, an ideal target for immunotherapy (Source: NIH, ClinicalTrials.gov). Therapeutic strategies targeting this complex include peptide vaccines like SurVaxM, T-cell receptor (TCR) engineered T-cells, and TCR-mimic antibodies (Source: MimiVax, SurVaxM Product Info). These therapies aim to trigger a specific immune response by recognizing the Survivin-derived peptide fragments displayed within the MHC groove, leading to the selective destruction of cancer cells (Source: Journal of Hematology & Oncology, 2019). By targeting the pMHC complex, these drugs can address the intracellular nature of Survivin, which is otherwise difficult to target with traditional monoclonal antibodies.

Other names

Survivin peptide–HLA class I complexSurvivin-pMHCBIRC5-HLA complexSurvivin-HLA-A*02:01 complexBaculoviral IAP repeat-containing protein 5 peptide–HLA complex

Recognition of the peptide-MHC complex by T-cell receptors (TCRs) or TCR-mimic agents, leading to the activation of cytotoxic immune responses and selective lysis of tumor cells expressing the BIRC5-derived antigen.